Artiva Biotherapeutics (ARTV) Cash from Operations (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash from Operations data on file, last reported at 20950000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 20950000.0, down 5.59% year-over-year; the trailing twelve-month figure through Mar 2026 was 77909000.0 (down 30.31% YoY), and the FY2025 annual result was 76800000.0, down 39.56% from the prior year.
• Cash from Operations slipped to 20950000.0 in Q1 2026 per ARTV's latest filing, from 14775000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 10675000.0 in Q4 2023 and troughed at 22983000.0 in Q2 2025.
• A 4-year average of 15836818.18 and a median of 14775000.0 in 2025 frame the typical range for Cash from Operations.
• On a YoY basis, Cash from Operations climbed as much as 0.85% in 2025 and fell as far as 67.94% in 2025.
• A 4-year view of Cash from Operations shows it stood at 10675000.0 in 2023, then tumbled by 37.24% to 14650000.0 in 2024, then decreased by 0.85% to 14775000.0 in 2025, then slumped by 41.79% to 20950000.0 in 2026.
• Business Quant data shows ARTV's Cash from Operations at 20950000.0 in Q1 2026, 14775000.0 in Q4 2025, and 19201000.0 in Q3 2025.